Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 or huMNC2-CAR22, Specific for a Cleaved Form of MUC1 (MUC1*)

NCT04020575 is registered in ClinicalTrials.gov with Minerva Biotechnologies Corporation as lead sponsor.

NCT NCT04020575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04020575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 or huMNC2-CAR22, Specific for a Cleaved Form of MUC1 (MUC1*)
Lead sponsor
Minerva Biotechnologies Corporation
Phase
Phase 1
Overall status
Recruiting
Start date
January 15, 2020
Completion date
January 15, 2035
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer